INVESTOR NOTICE: GRAIL, Inc. (GRAL) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action- Hagens Berman

Commercial stage healthcare company GRAIL focuses on early cancer detection. The litigation focuses on the propriety of GRAIL's disclosures about the design of its NHS-Galleri trial (the "trial") and the likelihood it would meet its primary endpoint – with three consecutive years of follow-up screening, the absolute reduction in the number of late stage (stages 3 and 4) cancer diagnoses. During the Class Period, GRAIL expressed high confidence in the trial's design and likely outcomes. They consistently stated that the three-year duration was specifically chosen to demonstrate a statistically significant reduction in combined stage 3 and 4 cancers. The complaint alleges that GRAIL misled investors by creating the false impression that it possessed reliable information supportive of the probability of the trial achieving its primary endpoint. The complaint further alleges that GRAIL's expressed optimism was unrealistic because, unknown to investors, the compa...